Euclidean Capital LLC: FOGHORN THERAPEUTICS INC (FHTX): Quarterly 13F Position History
As of Q1 2026, Euclidean Capital LLC reported 1,573,761 shares of FOGHORN THERAPEUTICS INC (FHTX), worth $7.5M and representing 1.9% of its 13F equity book. The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 1,573,761Shares Held (Latest Filing)
- $7.5MReported Market Value (Latest Filing)
- 1.9%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$975.7KQuarter-over-Quarter Value Change
- 1,573,761Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,573,761 | 0 | — | $7.5M | 1.9% | $4.8 |
| Q4 2025 | 1,573,761 | 0 | — | $8.5M | 2.3% | $5.4 |
| Q3 2025 | 1,573,761 | 0 | — | $7.7M | 3.2% | $4.9 |
| Q2 2025 | 1,573,761 | 0 | — | $7.4M | 2.4% | $4.7 |
| Q1 2025 | 1,573,761 | 0 | — | $5.7M | 2.2% | $3.6 |
| Q4 2024 | 1,573,761 | 0 | — | $7.4M | 1.0% | $4.7 |
| Q3 2024 | 1,573,761 | 0 | — | $14.7M | 1.6% | $9.3 |
| Q2 2024 | 1,573,761 | 0 | — | $9.0M | 1.1% | $5.8 |
| Q1 2024 | 1,573,761 | 0 | — | $10.6M | 1.4% | $6.7 |
| Q4 2023 | 1,573,761 | 0 | — | $10.2M | 1.1% | $6.5 |
| Q3 2023 | 1,573,761 | 0 | — | $7.9M | 1.7% | $5.0 |
| Q2 2023 | 1,573,761 | +312,500 | +24.8% | $11.1M | 2.8% | $7.0 |
| Q1 2023 | 1,261,261 | 0 | — | $7.8M | 6.9% | $6.2 |
| Q4 2022 | 1,261,261 | 0 | — | $8.0M | 7.5% | $6.4 |
| Q3 2022 | 1,261,261 | 0 | — | $10.8M | 10.0% | $8.6 |
| Q2 2022 | 1,261,261 | 0 | — | $17.2M | 14.6% | $13.6 |
| Q1 2022 | 1,261,261 | 0 | — | $19.2M | 11.2% | $15.2 |
| Q4 2021 | 1,261,261 | 0 | — | $28.8M | 16.4% | $22.9 |
| Q3 2021 | 1,261,261 | 0 | — | $17.6M | 8.5% | $13.9 |
| Q2 2021 | 1,261,261 | 0 | — | $13.5M | 3.1% | $10.7 |
| Q1 2021 | 1,261,261 | 0 | — | $16.6M | 5.6% | $13.2 |
| Q4 2020 | 1,261,261 | — | — | $25.6M | 5.4% | $20.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Euclidean Capital LLC first disclose a FHTX position in 13F-HR filings?
Euclidean Capital LLC first reported FOGHORN THERAPEUTICS INC (FHTX) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Euclidean Capital LLC's most recent quarter-over-quarter share-count change in FHTX?
Euclidean Capital LLC held the same 1,573,761 shares of FHTX between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Euclidean Capital LLC's cost basis in FHTX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.